“We took an overnight decision, packed two suitcases, and booked a flight back to India,” he recalls. The losses, during the same period, looked pony in the context of ballooning revenue: Rs4.5 crore to Rs29.05 crore. A cocktail of two drugs—China-Plus-One strategy globally, and an import substitution by Indian players domestically—turned out to steroid-induced growth for Zetwerk. A cocktail of two drugs—China-Plus-One strategy globally, and an import substitution by Indian players domestically—turned out to steroid-induced growth for Zetwerk. “Overnight, this (TV) emerged [as] a category for us,” recounts Amrit Acharya, co-founder and chief executive officer of Zetwerk.

Source: Forbes September 26, 2022 08:05 UTC